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Cholinergic Pruritus responding to Omalizumab: a case report 
 
Cholinergic pruritus is a rare condition characterised by generalised itch provoked by 
sweating without an associated rash. It is exacerbated by heat, exercise, emotion or 
activities of daily living.(1) The pruritus can be severe and have a considerable 
impact on the patient’s life. 
A 60 year old gentleman presented to our clinic in 2012 with a 9-month history of 
severe pruritus and a burning sensation that was induced by exercise and heat and 
relieved by cooling. The symptoms were not associated with a skin rash. His 
Dermatology Life Quality Index (DLQI) score of 23/30 indicated an extremely large 
effect on his quality of life. The pruritus impacted many of his regular daily activities 
like housework and shopping, including sexual activity. The patient had a history of 
asthma and depression for which he was taking fluticasone salmeterol and 
sertraline. On examination, there were a few patches of vitiligo covering around 2% 
of his BSA but no other skin lesions and no dermographism. A blood test screen 
(complete blood count, lactate dehydrogenase, liver, renal and thyroid function test, 
HbA1c, IgA anti-tissue transglutaminase antibody and pemphigoid antibody) for 
systemic causes of pruritus without rash yielded negative results.    
Initial treatment for the cholinergic pruritus included a trial of several antihistamines 
including fexofenadine 180 mg BD, in addition to ranitidine 150 mg BD and 
montelukast 10 mg OD. Increasing the doses of antihistamine was not possible due 
to sedation on higher doses. Danazol 200 mg TDS, subsequently tapered down to 
100 mg OD, was added to his treatment regimen based on case report evidence in 
cholinergic pruritus.(2) His symptoms improved but after 2 years of therapy the 
patient developed tenderness in the left breast and mild gynaecomastia and danazol 
was discontinued. As a result, a trial of monthly subcutaneous injections of 
omalizumab 300 mg was initiated. 
Prior to initiating omalizumab, the patient reported a DLQI score of 19/30 and Itch 
numeric rating scale (NRS) score of 8/10. Three months after starting omalizumab 
the patient experienced a dramatic improvement in his symptoms with a DLQI score 
of 3/30 and Itch NRS score of 0-1/10 (Figure.1). His scores in regards to itching, 
interference with regular chores, choice of clothes, sports and work were reduced 
with the disease having very little or no impact at all on these areas. The patient 
initially reported that there was complete resolution of his symptoms in the 2 weeks 
after receiving the omalizumab injection, and mild pruritus in the following 2 weeks. 
This has gradually improved and the patient reports that he no longer has any 
symptoms in between the injections. The slight increase in the patient’s DLQI score 
in April 2019 to 8/30 was probably due to incorrect administration of omalizumab 
injection intramuscularly that month because the patient reported the injection was 
more painful than usual.  
Cholinergic pruritus is a rare disease that may go undiagnosed due to the lack of 
physical signs or misdiagnosed as cholinergic pruritus.(3) In our patient danazol 
somewhat alleviated his pruritus but led to the development of breast tenderness 
and gynecomastia. The patient was started on omalizumab based on reports of its 
benefit in treating cholinergic urticaria.(4, 5) Omalizumab was effective in controlling 
the patient’s symptoms and he was able to resume his regular physical activities 
including physiotherapy sessions for a shoulder injury. To our knowledge, this is the 
first report of cholinergic pruritus being treated with omalizumab, which is a treatment 
option worth considering for severe refractory cholinergic pruritus.  
 
 
 
 
 
  Figure1. Figure outlining DLQI* and Itch NRS** scores over time. Omalizumab was 
commenced in June 2018.  
*DLQI Dermatology Life Quality Index  
**Itch NRS Itch Numerical Rating Scale  
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